Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.2.0.727
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Unaudited Consolidated Statements Of Operations        
Revenues        
Operating expenses:        
Amortization & depreciation $ 185 $ 194 $ 369 $ 388
General and administrative 103,960 156,285 189,231 294,911
Total operating expenses 104,145 156,479 189,600 295,299
Loss from operations $ (104,145) (156,479) (189,600) (295,299)
Other income (expense):        
Gain (Loss) on fair value adjustment - derivatives   $ 1,791 25,456 $ (8,260)
Gain on debt reversal $ 485   485  
Interest expense (57,104) $ (45,811) (112,518) $ (87,665)
Interest expense - beneficial conversion feature (7,500) (9,001) (11,250) (19,665)
Total other income (expense) (64,119) (53,021) (97,827) (115,590)
Loss before provision for income taxes $ (168,264) $ (209,500) $ (287,427) $ (410,889)
Provision for income tax        
Net loss $ (168,264) $ (209,500) $ (287,427) $ (410,889)
Less: Net loss attributable to noncontrolling interest 933 1,173 1,867 2,367
Net loss attributable to TranBioTec, Inc. $ (167,331) $ (208,327) $ (285,560) $ (408,522)
Net loss per share        
(Basic and fully diluted) $ (0.00) $ (0.01) $ (0.00) $ (0.01)
Weighted average number of common shares outstanding 58,655,062 36,539,241 58,536,520 35,773,532